Activation and self-tolerance of natural killer cells

Immunological Reviews

Volumn 214, Issue 1, 2006, Pages 130-142

  Gasser, Stephan ^a   Raulet, David H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DNA damage response; Hyporesponsiveness; Innate immunity; Natural killer cells; Tolerance; Tumor immunology

Indexed keywords

DNA; DNA VACCINE; IONOMYCIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN KINASE C ACTIVATOR;

CANCER; CANCER CELL; CARCINOGENESIS; CELL ACTIVATION; CELL SURFACE; CYTOLOGY; CYTOLYSIS; CYTOTOXICITY; DNA DAMAGE; GENETIC PREDISPOSITION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; NATURAL KILLER CELL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRESS; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY; UPREGULATION;

ANIMALS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; SELF TOLERANCE;

EID: 33750730609     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00460.x     Document Type: Review

References (110)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
2. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
3. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Eng J Med 1989;320:1731-1735.
4. Unanue ER. Studies in listeriosis show the strong symbiosis between the innate cellular system and the T-cell response. Immunol Rev 1997;158:11-25.
5. Laskay T, Röllinghoff M, Solbach W. Natural killer cells participate in the early defense against Leishmania major infection in mice. Eur J Immunol 1993;23:2237-2241.
6. Scharton TM, Scott P. Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567-577.
7. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 1975;16:216-229.
8. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-117.
9. Seaman W, Sleisenger M, Eriksson E, Koo G. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 1987;138:4539-4544.
10. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T cell immunity. Immunol Rev 2002;188:9-21.
11. Murphy W, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immunodeficiency (SCID). J Exp Med 1987;165:1212-1217.
12. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
13. Moretta A, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
14. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001;19:291-330.
15. Yokoyama WM, Seaman WE. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. Annu Rev Immunol 1993;11:613-635.
16. Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 2006;18:145-150.
17. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986;319:675-678.
18. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
19. Bix M, Liao N-S, Zijlstra M, Loring J, Jaenisch R, Raulet D. Rejection of class I MHC-deficient hemopoietic cells by irradiated MHC-matched mice. Nature 1991;349:329-331.
20. Liao N, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science 1991;253:199-202.
21. - bone marrow in chimeric mice. Proc Natl Acad Sci USA 1991;88:10332-10336.
22. Oberg L, et al. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur J Immunol 2004;34:1646-1653.
23. Yokoyama WM. Natural killer cell receptors specific for major histocompatibility complex class I molecules. Proc Natl Acad Sci USA 1995;92:3081-3085.
24. Moretta A, et al. Receptors for HLA class-I molecules in human natural killer cells. Ann Rev Immunol 1996;14:619-648.
25. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B, and C. Nature 1998;391:795-799.
26. b. J Exp Med 1998;188:1841-1848.
27. + IL-2 activated natural killer cells. Nature 1992;358:66-70.
28. Moretta A, et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172:1589-1598.
29. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-408.
30. Wagtmann N, et al. Molecular clones of the p58 natural killer cell receptor reveal Ig-related molecules with diversity in both the extra- and intra-cellular domains. Immunity 1995;2:439-449.
31. Raulet DH, Held W, Correa I, Dorfman J, Wu M-F, Corral L. Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev 1997;155:41-52.
32. Valiante N, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-751.
33. Kubota A, Kubota S, Lohwasser S, Mager DL, Takei F. Diversity of NK cell receptor repertoire in adult and neonatal mice. J Immunol 1999;163:212-216.
34. Tanamachi DM, Hanke T, Takizawa H, Jamieson AM, Raulet DH. Expression of natural killer cell receptor alleles at different Ly49 loci occurs independently and is regulated by major histocompatibility complex class I molecules. J Exp Med 2001;193:307-315.
35. Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med 1998;188:2083-2090.
36. Carlyle JR, Jamieson AM, Gasser S, Clingan CS, Arase H, Raulet DH. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc Natl Acad Sci USA 2004;101:3527-3532.
37. Iizuka K, Naidenko OV, Plougastel BF, Fremont DH, Yokoyama WM. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol 2003;4:801-807.
38. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005;6:938-945.
39. George TC, Ortaldo JR, Lemieux S, Kumar V, Bennett M. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J Immunol 1999;163:1859-1867.
40. Raulet DH, Vance RE. Self-tolerance of natural killer cells. Nat Rev Immunol 2006;6:520-531.
41. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004;23:255-259.
42. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003;3:781-790.
43. Correa I, Corral L, Raulet DH. Multiple natural killer cell-activating signals are inhibited by major histocompatibility complex class I expression in target cells. Eur J Immunol 1994;24:1323-1331.
44. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-126.
45. Cerwenka A, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
46. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
47. Pende D, et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001;31:1076-1086.
48. Cosman D, et al. ULBPs, novel MHC class Irelated molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
49. Perussia B. Fc receptors on natural killer cells. Curr Top Microbiol Immunol 1998;230:63-88.
50. Brown MG, et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001;292:934-937.
51. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002;296:1323-1326.
52. Mandelboim O, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409:1055-1060.
53. Nakamura MC, et al. Mouse Ly-49D recognizes H-2D(d) and activates natural killer cell cytotoxicity. J Exp Med 1999; 189:493-500.
54. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102:13224-13229.
55. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001;181:170-184.
56. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
57. Groh V, Smythe K, Dai Z, Spies T. Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 2006;7:755-762.
58. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003;100:9452-9457.
59. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679.
60. Andre P, et al. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors. Eur J Immunol 2004;34:961-971.
61. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8 αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001;2:255-260.
62. Markiewicz MA, et al. Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005;175:2825-2833.
63. Meresse B, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-366.
64. Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732.
65. Diefenbach A, et al. Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 2002;3:1142-1149.
66. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003;4:557-564.
67. Zompi S, et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol 2003;4:565-572.
68. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger natural killer cell activation and costimulation. Nat Immunol 2002;3:1150-1155.
69. Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J Immunol 2004;173:2470-2478.
70. Roberts AI, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001;167:5527-5530.
71. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996;93:12445-12450.
72. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
73. Salih HR, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003;102:1389-1396.
74. Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity. Eur J Immunol 2003;33:2033-2043.
75. Raffaghello L, et al. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004;6:558-568.
76. Nomura M, Zou Z, Joh T, Takihara Y, Matsuda Y, Shimada K. Genomic structures and characterization of Rae1 family members encoding GPI-anchored cell surface proteins and expressed predominantly in embryonic mouse brain. J Biochem 1996;120:987-995.
77. Welte SA, et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 2003;33:194-203.
78. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T. Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 2003;170:4196-4200.
79. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436: 1186-1190.
80. Sancar A, Lindsey-Boltz LA, Unsal-Kaccmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
81. Gorgoulis VG, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-913.
82. Bartkova J, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-870.
83. Weitzman MD, Carson CT, Schwartz RA, Lilley CE. Interactions of viruses with the cellular DNA repair machinery. DNA Repair (Amst) 2004;3:1165-1173.
84. Ishikawa T, et al. DNA repair and cancer: lessons from mutant mouse models. Cancer Sci 2004;95:112-117.
85. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res 2006;66:3959-3962.
86. Hoglund P. DNA damage and tumor surveillance: one trigger for two pathways. Sci STKE 2006;2006:pe2.
87. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-171.
88. Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y. Cutting edge: novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J Immunol 2004;172:757-761.
89. Zhou H, et al. DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor. Proc Natl Acad Sci USA 2005;102:10846-10851.
90. Oppenheim DE, et al. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 2005;6:928-937.
91. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. NKG2D function protects the host from tumor initiation. J Exp Med 2005;202: 583-588.
92. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-738.
93. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006;66:2520-2526.
94. Krmpotic A, et al. MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 2002;3:529-535.
95. Lodoen M, et al. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003;197:1245-1253.
96. Gourzi P, Leonova T, Papavasiliou FN. A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 2006;24:779-786.
97. Ljunggren H-G, Van Kaer L, Ploegh HL, Tonegawa S. Altered natural killer cell repertoire in Tap-1 mutant mice. Proc Natl Acad Sci USA 1994;91:6520-6524.
98. Hoglund P, et al. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains. Eur J Immunol 1998;28:370-378.
99. Grigoriadou K, Menard C, Perarnau B, Lemonnier FA. MHC class Ia molecules alone control NK-mediated bone marrow graft rejection. Eur J Immunol 1999;29:3683-3690.
100. Zimmer J, et al. Activity and phenotype of natural killer cells in peptide transporter (TAP)-deficient patients (type I bare lymphocyte syndrome). J Exp Med 1998;187:117-122.
101. - mice. J Immunol 1997;159:5219-5225.
102. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lemieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-4423.
103. Kim S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436: 709-713.
104. Yu YY, George T, Dorfman J, Roland J, Kumar V, Bennett M. The role of Ly49A and 5E6 (Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 1996;4:67-76.
105. Hanke T, et al. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 1999;11:67-77.
106. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006;24:249-257.
107. MacDonald HR. NK cell tolerance: revisiting the central dogma. Nat Immunol 2005;6:868-869.
108. Wu M-F, Raulet DH. Class I-deficient hematopoietic cells and non-hematopoietic cells dominantly induce unresponsiveness of NK cells to class I-deficient bone marrow grafts. J Immunol 1997;158:1628-1633.
109. Johansson MH, Bieberich C, Jay G, Karre K, Hoglund P. Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med 1997;186:353-364.
110. Johansson MH, Hoglund P. Low number of H-2Dd-negative haematopoietic cells in mixed bone marrow chimeras convey in vivo tolerance to H-2Dd-negative cells but fail to prevent resistance to H-2Dd-negative leukaemia. Scand J Immunol 2004;59:71-78.